UNCITI-BROCETA GROUP
Edinburgh Cancer Research UK Centre, MRC Institute of Genetics & Molecular Medicine
University of Edinburgh
PUBLICATIONS
(102) C. Adam, A. Lorente-Macías, S. Croke and A. Unciti-Broceta*. Chapter 14 Bioorthogonal Strategies for the Uncaging and Assembly of Drugs. Science of Synthesis: Abiotic Reactions in Live Environments. (Ed: Mascareñas, J. L. et al.). 2024, DOI: 10.1055/sos-SD-242-00020.
(101) E. A. Said, R. W. Lewis, M. L. Dallas, C. Peers, F. A. Ross, A. Unciti-Broceta, D. G. Hardie, A. M. Evans. The thienopyridine A-769662 and benzimidazole 991 inhibit human TASK-3 potassium channels in an AMPK-independent manner. Biochemical Pharmacology 2024, DOI: 10.1016/j.bcp.2024.116562.
(100) E. Nestoros, F. de Moliner, F. Nadal-Bufi, D. Seah, M. C. Ortega-Liebana, S. Benson, Z. Cheng, C. Adam, L. Maierhofer, K. Kozoriz, J.-S. Lee, A. Unciti-Broceta* and M. Vendrell*. Tuning singlet oxygen generation with caged organic photosensitizers. Nature Communications 2024, 15, 7689.
(99) S. Dash, S. Hanson, B. King, K. Nyswaner, K. Foss, N. Tesi, M. J. B. Harvey, S. A. Navarro-Marchal, Allison Woods, E. Poradosu, A. Unciti-Broceta, N. O. Carragher and John Brognard*. The SRC family kinase inhibitor NXP900 demonstrates potent anti-tumor activity in squamous cell carcinomas. Journal of Biological Chemistry 2024, 107615.
(98) E. Rebrov* and A. Unciti-Broceta*. Unconventional Catalysis in the Countryside. Catalysis Today 2024, 114813.
(97) M. Sanch-Albero,* V. Sebastian, A. M. Pérez-López, P. Martin-Duque,* A. Unciti-Broceta & J. Santamaría. Extracellular Vesicles-Mediated Bio-Orthogonal Catalysis in Growing Tumors. Cells 2024, 13, 691.
(96) R. L. Hollis,* R. Elliott, J. C. Dawson, N. Ilenkovan, R. M. Matthews, L. J. Stillie, A. J. Oswald, H. Kim, M. L. Fernandez, M. Churchman, J. M. Porter, P. Roxburgh, A. Unciti-Broceta, D. M. Gershenson, C. S. Herrington, M. S. Carey, N. O. Carragher, C. Gourley. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecologic Oncology 2024, 186, 42-52.
(95) M. van de L'Isle, S. Croke, T. Valero, A. Unciti-Broceta*. Development of Biocompatible Cu(I)-Microdevices for Bioorthogonal Uncaging and Click Reactions. Chemistry, a European Journal 2024, e202400611.
(94) N. O. Carragher, E. Poradosu, B. King, A. F. Munro, J. C. Dawson and A. Unciti-Broceta. NXP900, a novel YES1/SRC kinase inhibitor in phase 1, demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors. Cancer Research 2024, 84, 615.
(93) L. Deng, A. Sathyan, C. Adam, A. Unciti-Broceta, V. Sebastian, A. R. A. Palmans*. Enhanced Efficiency of Pd(0)-Based Single Chain Polymeric Nanoparticles for in Vitro Prodrug Activation by Modulating the Polymer’s Microstructure. Nano Letters 2024, 24, 2242–2249.
(92) J. Braun, M. C. Ortega-Liebana, A. Unciti-Broceta, S. A. Sieber*. A Pd-labile fluoroquinolone prodrug efficiently prevents biofilm formation on coated surfaces. Organic & Biomolecular Chemistry 2024, 22, 1998-2002.
.
(91) A. Unciti-Broceta* and E. Rebrov*. Catalysis on the move. Catalysis Science & Technology 2024, 14, 512-514.
(90) R. E. Graham, R. Zheng, J. Wagner, A. Unciti-Broceta, D. C. Hay, S. J. Forbes, V. L. Gadd and N. O. Carragher*. Single-cell morphological tracking of liver cell states to identify small-molecule modulators of liver differentiation. BioRxiv 2023, https://doi.org/10.1101/2023.11.15.567184.
(89) S. Liu,* V. M. Rotello,* A. Unciti-Broceta* and H. Wei*. Introduction to nanozymes. Journal of Materials Chemistry B 2023, 11, 10979-10981.
(88) S. Navarro-Marchal, M. Harvey, B. King, R. E. Hughes, V. G. Brunton, S. Shemesh, E. Poradosu, A. Unciti-Broceta and N. O. Carragher. In vivo studies demonstrate differences in target inhibition and anticancer efficacy between NXP900 and dasatinib in ovarian clear cell carcinoma model. Cancer Research 2022, 83, 4031-4031.
(87) N. O. Carragher, S. Dash, K. Nyswaner, M. J. B. Harvey, B. King, A. Woods, A. Unciti-Broceta, E. Poradosu and J. Brognard. NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models. Molecular Cancer Therapeutics 2023, 22, B162.
(86) D. J. Baillache, T. Valero, Á. Lorente-Macías, D. J. Bennett, R. J. R. Elliott, N. O. Carragher and A. Unciti-Broceta*. Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells. RSC Medicinal Chemistry 2023, 15, 2611-2624.
(85) V. Smer-Barreto,* A. Quintanilla, R. J. R. Elliott, J. C. Dawson, J. Sun, V. M. Campa, Á. Lorente-Macías, A. Unciti-Broceta, N. O. Carragher, J. C. Acosta,* D. A. Oyarzún.* Discovery of senolytics using machine learning. Nature Communications 2023, 14, 3445.
(84) X.-F. Li, C. Selli, H.-L. Zhou, J. Cao, S. Wu, R.-Y. Ma, Y. Lu, C.-B. Zhang, B. Xun, A. D. Lam, X.-C. Pang, A. Fernando, Z. Zhang, A. Unciti-Broceta, N. O. Carragher, P. Ramachandran, N. C. Henderson, L.-L. Sun, H.-Y. Hu, G.-B. Li, C. Sawyers,* B.-Z. Qian.* Macrophages promote anti-androgen resistance in prostate cancer bone disease. Journal of Experimental Medicine 2023, 220, e20221007.
(83) Belén Rubio-Ruiz, A. M. Pérez-López, L. Uson, M. C. Ortega-Liebana, T. Valero, M. Arruebo, J. L. Hueso,* V. Sebastian,* J. Santamaria,* A. Unciti-Broceta.* In Cellulo Bioorthogonal Catalysis by Encapsulated AuPd Nanoalloys: Overcoming Intracellular Deactivation. Nano Letters 2023, 23, 804-811.
(82) A. Sathyan, S. Croke, A. M. Pérez-López, B. F. M. de Waal, A. Unciti-Broceta, A. R. A. Palmans.* Developing Pd (II) based amphiphilic polymeric nanoparticles for pro-drug activation in complex media. Molecular Systems Design & Engineering, 2022, 7, 1736-1748.
Covered by specialized media.
(81) S. Y. Chow, A. Unciti-Broceta.* Targeted Molecular Construct for Bioorthogonal Theranostics of PD-L1-Expressing Cancer Cells. JACS Au, 2022, 2, 1747-1756.
Highlighted in When the Chemistry Clicks and included in the Bioorthogonal and Click Chemistry Virtual Issue (curated by Nobel Prize Laureate Carolyn R. Bertozzi).
(80) H. Beetham, B. G. C. Griffith, O. Murina, A. E. P. Loftus, D. A. Parrey, J. Culley, M. Muir, A. Unciti-Broceta, A. H. Sims, A. Byron, V. G. Brunton.* Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors. Cancer Research, 2022, 82, 632-647.
Covered by specialized media.
(79) B. King, R. E. Hughes, S. Navarro-Marchal, V. G. Brunton, E. Poradosu, N. O. Carragher and A. Unciti-Broceta. Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles. European Journal of Cancer 2022, 174, S113.
(78) N. O. Carragher, R. Hughes, V. Brunton, A. Unciti-Broceta, I. Lanzagorta-Calvillo, C. Temps and E. Poradosu. Uncovering the molecular mechanisms which predict sensitivity to a novel Src kinase inhibitor NXP900 to inform personalized healthcare strategies. Cancer Research 2022, 82, 3326.
(77) X.-F. Li, C. Selli, A. Unciti-Broceta, N. O. Carragher, H.-Y. Hu, C. L. Sawyers and B.-Z. Qian. Macrophage promotion of anti-androgen resistance in prostate cancer bone disease. Cancer Immunology Research 2022, 10, PR09.
(76) C. Adam, T. L. Bray, A. M. Pérez-López, E. H. Tan, B. Rubio-Ruiz, D. J. Baillache, D R. Houston, M. J. Salji, H. Y. Leung & A. Unciti-Broceta.* A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo. Journal of Medicinal Chemistry, 2022, 65, 552-561.
Part of the Special Issue on New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science.
(75) M. C. Ortega-Liebana, N. J. Porter, C. Adam, T. Valero, L. Hamilton, D. Sieger, C. G. Becker & A. Unciti-Broceta.* Truly-biocompatible gold catalysis enables vivo-orthogonal intra-CNS release of anxiolytics. Angewandte Chemie Int. Ed., 2022, 61, e202111461.
.
(74) C. C. Ayala-Aguilera, T. Valero, Á. Lorente-Macías, D. J. Baillache, S. Croke & A. Unciti-Broceta.* Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 2022, 65, 1047-1131.
Part of the Special Issue on New Horizons in Drug Discovery - Understanding and Advancing Different Types of Kinase Inhibitors.
(73) C. Temps, D. Lietha, E. R. Webb, X.-F. Li, J. C. Dawson, M. Muir, K. G. Macleod, T. Valero, A. F. Munro, R. Contreras-Montoya, J. R. Luque-Ortega, C. Fraser, H. Beetham, C. Schoenherr, M. Lopalco, M. J. Arends, M. C. Frame, B.-Z. Qian, V. G. Brunton, N. O. Carragher & A. Unciti-Broceta.* A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. Cancer Research, 2021, 81, 5438-5450.
Widely covered by specialized and mainstream media.
(72) N. Martinez-Peinado, Á. Lorente-Macías, A. García-Salguero, N. Cortes-Serra, Á. Fenollar-Collado, A. Ros-Lucas, J. Gascon, M.-J. Pinazo, I. J. Molina, A. Unciti-Broceta, J. J. Díaz-Mochón, M. J. Pineda de las Infantas y Villatoro, L. Izquierdo & J. Alonso-Padilla.* Novel Purine Chemotypes with Activity against Plasmodium falciparum and Trypanosoma cruzi. Pharmaceuticals, 2021, 14, 638.
(71) B. Rubio-Ruiz,* A. M. Pérez-López, V. Sebastián & A. Unciti-Broceta.* A minimally-masked inactive prodrug of panobinostat that is bioorthogonally activated by gold chemistry Bioorganic & Medicinal Chemistry, 2021, 41, 116217.
(70) J. D. G. Leach, N. Vlahov, P. Tsantoulis, R. A. Ridgway, D. J. Flanagan, K. Gilroy, N. Sphyris, E. G. Vázquez, D. F. Vincent, W. J. Faller, M. C. Hodder, A. Raven, S. Fey, A. K. Najumudeen, D. Strathdee, C. Nixon, M. Hughes, W. Clark, R. Shaw, S. R. van Hooff, D. J. Huels, J. P. Medema, S. T. Barry, M. C. Frame, A. Unciti-Broceta, S. J. Leedham, G. J. Inman, R. Jackstadt, B. J. Thompson, A. D. Campbell, S. Tejpar & O. J. Sansom.* Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis. Nature Communications 2021, 12, 3464.
(69) Á. Lorente-Macías, J. J. Díaz-Mochón, M. J. P. de las Infantas y Villatoro & A. Unciti-Broceta.* Design and Synthesis of 9-Dialkylamino-6-[(1H-1, 2, 3-triazol-4-yl)methoxy]-9H-purines. ChemRxiv 2021, DOI: 10.26434/chemrxiv.13664516.v1 .
(68) V. Sebastian,* M. Sanch-Albero, M. Arruebo, A. M. Pére-López, B. Rubio-Ruiz, P. Martin-Duque, A. Unciti-Broceta & J. Santamaría. Nondestructive production of exosomes loaded with ultrathin palladium nanosheets for targeted bio-orthogonal catalysis. Nature Protocols 2021, 16, 131-163.
(67) M. O.N. van de L'Isle, M. C. Ortega-Liebana and A. Unciti-Broceta*. Transition metal catalysts for the bioorthogonal synthesis of bioactive agents. Current Opinion in Chemical Biology 2021, 61, 32-42.
(66) D. J. Baillache and A. Unciti-Broceta*. Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. RSC Medicinal Chemistry 2020,11, 1112-1135.
(65) A. M. Pérez-López, B. Rubio-Ruiz, T. Valero, R. Contreras-Montoya, L. Álvarez de Cienfuegos, V. Sebastián, J. Santamaría and A. Unciti-Broceta*. Bioorthogonal uncaging of cytotoxic paclitaxel through Pd nanosheet-hydrogel frameworks. Journal of Medicinal Chemistry 2020, 63, 9650-9659.
(64) J. Santamaría* and A. Unciti-Broceta*. Bioorthogonal catalysis goes chiral. Chem 2020, 6, 1853-1855.
(63) J. Sergeys, I. Van Hove, T.-T. Hu, C. Temps, N. O. Carragher, A. Unciti-Broceta, J. H. M. Feyen, L. Moons and M. Porcu*. The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific SRC family kinase inhibition in retinal vascular disease. Experimental Eye Research 2020, 197, 108108.
(62) T. Valero, D. Baillache, C. Fraser, S. H. Myers and A. Unciti-Broceta*. Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway Bioorganic & Medicinal Chemistry 2020, 28, 115215.
Part of the Special Issue on Phenotypic Drug Discovery.
PUBLICATIONS before 2020
(61) O. Cruz-López, C. Temps, B. Longo, S. H. Myers, F. Franco-Montalbán and A. Unciti-Broceta*. Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity ACS Omega 2019, 4, 21620-21626.
(60) M. Sancho-Albero, B. Rubio-Ruiz, A. M. Pérez-López, P. Martín-Duque, V. Sebastián, M. Arruebo, J. Santamaría* and A. Unciti-Broceta*. Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis. Nature Catalysis 2019, 2, 864-872.
Featured in News & Views in Nature Catalysis issue 10
Widely covered by specialized and mainstream media.
(59) H. W. Smith, A. Hirukawa, V. Sanguin-Gendreau, I. Nandi, C. R. Dufour, D. Zuo, K. Tandoc, M. Leibovitch, S. Singh, J. P. Rennhack, M. Swiatnicki, C. Lavoie, V. Papavasiliou, C. Temps, N. O. Carragher, A. Unciti-Broceta, P Savage, M. Basik, V. van Hoef, O. Larsson, Caroline L. Cooper, A. C. Vargas Calderon, Jane Beith, E. Millar, C. Selinger, V. Giguère, M. Park, L. N. Harris, V. Varadan, E. R. Andrechek, S. A. O’Toole, I. Topisirovic and W. J. Muller*. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications 2019, 10, 2901.
(58) N. Fernández-Sáez, Belén Rubio-Ruiz, J. M. Campos, A. Unciti-Broceta, M. D. Carrión* and M. E. Camacho*. Purine derivatives with heterocyclic moieties and related analogs as new antitumor agents. Future Medicinal Chemistry 2019, 11, 83-95.
(57) C. Torres-Sánchez,* A. M. Pérez-López, M. N. Alqahtani, A. Unciti-Broceta and B. Rubio-Ruiz. Design and manufacture of functional catalyst-carrier structures for the bioorthogonal activation of anticancer agents. New Journal of Chemistry 2019, 43, 1449-1458.
Featured as New Journal of Chemistry HOT ARTICLE
(56) C. Adam, A. M. Pérez-López, L. Hamilton, B. Rubio-Ruiz, T. L Bray, D. Sieger, P. M. Brennan* and A. Unciti-Broceta*. Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium‐Functionalized Microdevices. Chemistry, A European Journal 2018, 24, 16783-16790.
Featured as HOT PAPER and Frontispiece of issue 63
(55) S. Sarvi, R. Crispin, Y. Lu, L. Zeng, T. D. Hurley, D. R. Houston, A. von Kriegsheim, C.-H. Chen, D. Mochly-Rosen, M. Ranzani, M. E. Mathers, X. Xu, W. Xu, D. J. Adams, N. O. Carragher, M. Fujita, L. Schuchter, A. Unciti-Broceta, V. G. Brunton, E. E. Patton*. ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chemical Biology 2018, 25, 1456-1469.
Featured in the FRONT PAGE of issue 12.
2010 - present
(54) T. Valero, A. Delgado-Gonzalez, J. D. Unciti-Broceta, M. V. Cano-Cortes, A. M. Pérez-López, A. Unciti-Broceta,* R. M. Sanchez-Martin*. Drug “Clicking” on Cell-Penetrating Fluorescent Nanoparticles for In Cellulo Chemical Proteomics. Bioconjugate Chemistry 2018, 29, 3154–3160.
2010 - present
(53) T. L Bray, M. Salji, A. Brombin, A. M. Pérez-López, B. Rubio-Ruiz, L. C. A. Galbraith, E. E. Patton, H. Leung* and A. Unciti-Broceta*. Bright insights into Palladium-triggered local chemotherapy. Chemical Science 2018, 9, 7354-7361.
Featured as 2018 Chemical Science HOT ARTICLE
News covered by general media: Scotsman, The National.
(52) Á. Lorente-Macias, M. Benítez-Quesada, I. J. Molina, A. Unciti-Broceta, J. J. Díaz-Mochón and M. J. Pineda de las Infantas Villatoro*. 1H and 13C assignments of 6‐, 8‐, 9‐ substituted purines. Magnetic Resonance Chemistry 2018, 56, 852-859.
(51) S. H. Myers, C. Temps, V. G. Brunton and A. Unciti-Broceta*. Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening. Journal of Medicinal Chemistry 2018, 61, 2104–2110.
(50) B. Rubio-Ruiz, A. M. Pérez-López, T. L. Bray, M. Lee, A. Serrels, M. Prieto, M. Arruebo, N. O. Carragher, V. Sebastián and A. Unciti-Broceta*. High-Precision Photothermal Ablation using Biocompatible Palladium Nanoparticles and Laser Scanning Microscopy. ACS Applied Materials & Interfaces 2018, 10, 3341-3348.
(49) A. Delgado-Gonzalez, E. Garcia-Fernandez, T. Valero, M. V. Cano-Cortes, M. J. Ruedas-Rama, A. Unciti-Broceta, R. M. Sanchez-Martin, J. J. Diaz-Mochon* and A. Orte*. Metallofluorescent Nanoparticles for Multimodal Applications. ACS Omega 2018, 3, 144-153.
(48) L. Hamilton, D. Sieger, B. Rubio-Ruiz and A. Unciti-Broceta*. A novel zebrafish xenograft model for immunotherapeutic drug screening. Neuro-oncology 2018, 20, i14.
(47) C. Adam, B. Rubio-Ruiz, J. T. Weiss, P. Brennan and A. Unciti-Broceta*. Development of glioma prodrugs with site-specific activation by bioorthogonal palladium implants. Neuro-oncology 2018, 20, i24.
(46) B. Rubio-Ruiz, T. L. Bray, A. M. Pérez-López and A. Unciti-Broceta*. Masking Strategies for the Bioorthogonal Release of Anticancer Glycosides. In: Z. J. Witczak, R. Bielski (Eds), Coupling and Decoupling of Diverse Molecular Units in Glycosciences (2018). Springer, Cham.
(45) A. M. Pérez-López, B. Rubio-Ruiz, V. Sebastián, L. Hamilton, C. Adam, T. L. Bray, S. Irusta, P. M. Brennan, G. C. Lloyd-Jones, D. Sieger, J. Santamaría* and A. Unciti-Broceta*. Gold-Triggered Uncaging Chemistry in Living Systems. Angewandte Chemie International Edition 2017, 56, 12548-12552.
Featured in the Inside Back Cover
Widely covered by specialized and mainstream media:
BBC, Sputnik Int., RTE, The Medicine Maker ("The Golden Touch")
(44) B. Rubio-Ruiz, J. T. Weiss and A. Unciti-Broceta*. Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor. Journal of Medicinal Chemistry 2016, 59, 9974–9980.
(43) S. J. Warchal, A. Unciti-Broceta and Carragher*. Next-generation phenotypic screening. Future Medicinal Chemistry 2016, 8, 1331-1347.
(42) C. Fraser, J. C. Dawson, R. Dowling, D. R. Houston, J. T. Weiss, A. Munro, M. Muir, L. Harrington, S. P. Webster, M. C. Frame, V. G. Brunton, E. E. Patton, N. O. Carragher and A. Unciti-Broceta*. Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. Journal of Medicinal Chemistry 2016, 59, 4697–4710.
(41) H. Creedon, L. Gómez-Cuadrado, Ž. Tarnauskaitė, J. Balla, M. Canel, K. G. MacLeod, B. Serrels, C. Fraser, A. Unciti-Broceta, N. Tracey, T. Le Bihan, T. Klinowska, A. H. Sims, A. Byron* and V. G. Brunton*. Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy. Oncotarget 2016, 7, 11539-11552.
(40) C. Fraser, N. O. Carragher and A. Unciti-Broceta*. eCF309: a potent, selective and cell-permeable mTOR inhibitor. MedChemComm 2016, 7, 471-477.
Featured as HOT Article of 2016 and Inside Front Cover
Contribution to the themed collection "New Talent: Europe"
(39) S. H. Myers, V. G. Brunton and A. Unciti-Broceta*. AXL inhibitors in cancer: A medicinal chemistry perspective. Journal of Medicinal Chemistry 2016, 59, 3593–3608.
(38) A. Unciti-Broceta*. Bioorthogonal catalysis: Rise of the nanobots. Nature Chemistry 2015, 7, 538-539.
(37) M. J. Pineda de las Infantas, S. Torres-Rusillo, J. D. Unciti-Broceta, P. Fernandez-Rubio, M. A. Luque-Gonzalez, M. A. Gallo, A. Unciti-Broceta, I. J. Molina and J. J. Diaz-Mochon*. Synthesis of 6,8,9 poly-substituted purine analogue libraries as pro-apoptotic inducers of human leukemic lymphocytes and DAPK-1 inhibitors. Organic & Biomolecular Chemistry 2015, 13, 5224-5234.
(36) J. T. Weiss, N. O. Carragher and A. Unciti-Broceta*. Palladium-Mediated Dealkylation of N-Propargyl-Floxuridine as a Bioorthogonal Oxygen-Independent Prodrug Strategy. Scientific Reports 2015, 5, 9329.
(35) R. Crispin, N. Spockeli, V. Brunton, N. Carragher, C. Gourley, Douglas Houston, Asier Unciti-Broceta & E E. Patton. Targeting cancer stem cells using ALDH-dependent 5-nitrofuran pro-drugs. Molecular Cancer Therapeutics 2015, 14, C25.
(34) M. J. Pineda de las Infantas y Villatoro,* J. D. Unciti-Broceta, R. Contreras-Montoya, J. A. Garcia-Salcedo, M. A. Gallo Mezo, A. Unciti-Broceta* and J. J. Diaz-Mochon*. Amide-controlled, one-pot synthesis of tri-substituted purines generates structural diversity and analogues with trypanocidal activity. Scientific Reports 2015, 5, 9139.
(33) J. T. Weiss, C. Fraser, B. Rubio-Ruiz, S. Myers, R. Crispin, J. C. Dawson, V. G. Brunton, E. E. Patton, N. O. Carragher and A. Unciti-Broceta*. N-Alkynyl Derivatives of 5-Fluorouracil: Susceptibility to Palladium-Mediated Dealkylation and Toxigenicity in Cancer Cell Culture. Frontiers in Chemistry 2014, 2, 56.
(32) J. T. Weiss, J. C. Dawson, C. Fraser, W. Rybski, C. Torres-Sánchez, M. Bradley, E. E. Patton, N. O. Carragher and A. Unciti-Broceta*. Development and Bioorthogonal Activation of Palladium-Labile Prodrugs of Gemcitabine. Journal of Medicinal Chemistry 2014, 57, 5395-5404.
Featured as ACS’ Editor Choice.
(31) J. T. Weiss, J. C. Dawson, K. G. Macleod, C. Fraser, W. Ribski, C. Torres-Sánchez, E. E. Patton, M. Bradley, N. O. Carragher & A. Unciti-Broceta*. Extracellular Palladium-Catalyzed Dealkylation of 5-Fluoro-1-Propargyl-Uracil as a Bioorthogonally-Activated Prodrug Approach. Nature Communications 2014, 5, 3277.
Featured in C&EN (Issue 8, p. 6, News of The Week), Synform (July Issue, Synfacts 2014, 10(07), A90-92) and widely covered by specialized (Cosmos Magazine, Elsevier Materials Today, etc.) and mainstream media (>25 news outlets, e.g. STV, The Herald, The Scotsman, ScienceDaily, ABC, and translated into > 10 languages).
(30) L. H. Wong, A. Unciti-Broceta, R. White, M. Spitzer, M. Tyers & L. Harrington*. A yeast chemical genetic screen identifies new inhibitors of human telomerase. Chemistry & Biology 2013, 20, 333-340.
(29) M. R. Yusop*, A. Unciti-Broceta & M. Bradley. A Highly Sensitive Fluorescent Viscosity Sensor. Bioorganic & Medicinal Chemistry Letters 2012, 22, 5780-5783.
(28) A. Unciti-Broceta*, E. M. V. Johansson, R. M. Sánchez-Martín & M. Bradley*. Synthesis of Polystyrene Microspheres and Functionalization with Pd0 Nanoparticles to Perform Bioorthogonal Organometallic Chemistry in Living Cells. Nature Protocols 2012, 7, 1207-1218.
First definition of Bioorthogonal Organometallic (BOOM) Chemistry. News about the article was covered by the Daily Express (30 Jun 2012).
(27) A. Unciti-Broceta, J. J. Díaz Mochón, R. M. Sanchez-Martin* & M. Bradley*. The Use of Solid Supports to Generate Nucleic Acid Carrier. Accounts of Chemical Research 2012, 45, 1140–1152.
(26) P. Peramuhendige, S. Marino, A. Unciti-Broceta, S. H. Ralston & A. I. Idris. A novel small molecule inhibitor of TRAF-dependent signaling inhibits breast cancer-induced osteoclastogenesis and prevents osteolysis. Bone 2012, 50, S61-S62.
(25) N. Carragher*, A. Unciti-Broceta & D. Cameron. Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Medicinal Chemistry 2012, 4, 87-105.
(24) A. Liberska, A. Lilienkampf, A. Unciti-Broceta* & M. Bradley*. Solid-Phase Synthesis of Arginine-Based Double-Tailed Cationic Lipopeptides: Potent Nucleic Acid Carriers. Chemical Communications 2011, 47, 12774-12776.
Compounds described in this article were patented and licensed to Deliverics Ltd.
(23) K. Dhaliwal*, G. Escher, A. Unciti-Broceta, N. McDonald, A. J. Simpson, C. Haslett & M. Bradley*. Far Red and NIR Dye-Peptoid Conjugates for Efficient Immune Cell Labelling and Tracking in Preclinical Models. MedChemComm 2011, 2, 1050-1053.
Featured in the front cover of the No. 11 issue of MedChemComm.
(22) M. R. Yusop, A. Unciti-Broceta, R. M. Sánchez-Martín, E. M. V. Johansson & M. Bradley*. Palladium-Mediated Intracellular Chemistry. Nature Chemistry 2011, 3, 241–245.
Featured in Chemistry World (Issue 3, 2011, RSC) and Synform (May Issue, 2011, Thieme Publisher). News of the discovery was widely covered by general media: TV (STV), radio (BBC1) and press (The Times, The Scotsman, Metro, Scottish Daily Express, The Herald, etc.).
(21) A. Unciti-Broceta*, L. Moggio, K. Dhaliwal, K. Finlayson, C. Haslett & M. Bradley*. Safe and Efficient In Vitro and In Vivo Gene Delivery: Tripodal Cationic Lipids with Programmed Biodegradability. Journal of Materials Chemistry 2011, 21, 2154-2158.
Compounds described in this article were patented and licensed to Deliverics Ltd.
(20) K. Dhaliwal*, L. Alexander, G. Escher, A. Unciti-Broceta, M. Jansen, N. Mcdonald, J. M. Cardenas-Maestre, R. Sanchez-Martin, J. Simpson, C. Haslett & M. Bradley*. Multimodal Molecular Imaging approaches to detect primary cells in preclinical models. Faraday Discussions 2011, 149, 107-114.
Before 2010
(19) A. Unciti-Broceta*, M. N. Bacon & M. Bradley*. Chemical Strategies for the Preparation of Synthetic Transfection Vectors. Topics in Current Chemistry 2010, 296, 15-49.
Part of the Nucleic Acid Transfection Volume.
(18) A. Unciti-Broceta*. The 3rd International Symposium “Cellular Delivery of Therapeutic Macromolecules”. Therapeutic Delivery 2010, 1, 511–515.
(17) A. Unciti-Broceta*. MedChem Europe 2010 - Select Biosciences' Sixth Annual Meeting. IDrugs 2010, 13, 366–368.
Originally published by Thomson Pharma (2010, Thomson Reuters Scientific).
(16) Steve Howell, Mark Bradley & A. Unciti-Broceta. Non-toxic, highly efficient delivery of nucleic acids into challenging cells using SAFEctin transfection reagent. Drug Discovery Today 2010, 15, 1114.
(15) A. Unciti-Broceta, L. Moggio, K. Dhaliwal, L. Pidgeon, K. Finlayson, C. Haslett & M. Bradley. High-efficient transfection using cationic lipids with programmed biodegradability. Drug Discovery Today 2010, 15, 1111.
(14) A. Unciti-Broceta*, M. J. Pineda, M. A. Gallo & A. Espinosa. Synthesis of 9-alkyl-6-amino[1,2,4]triazolo[3,4-c]-5-azaquinoxalines. Mild and Effective SNAr Amination of Highly Electron-Poor Heterocycles. Tetrahedron Letters 2010, 51, 2262–2264.
(13) A. Unciti-Broceta, M. R. Yusop, P. Richardson, J. Walton & M. Bradley*. A fluorescein-derived anthocyanidin-inspired pH sensor. Tetrahedron Letters 2009, 50, 3713–3715.
Part of the special issue commemorating the 50th Anniversary of Tetrahedron Letters.
(12) A. Unciti-Broceta, F. Diezmann, C. Y. Ou-Yang, M. A. Fara, M. Bradley*. Synthesis, Penetrability and Intracellular Targeting of Fluorescein-Tagged Peptoids and Peptide-Peptoid Hybrids. Bioorganic & Medicinal Chemistry 2009, 17, 959-966.
Part of the special issue honouring the Tetrahedron Young Investigator Award 2006 “Jonathan Ellman”.
(11) A. Liberska, A. Unciti-Broceta & M. Bradley*. Very Long-Chain Fatty Tails for Enhanced Transfection. Organic & Biomolecular Chemistry 2009, 7, 61-68.
(10) S. Pernagallo,† A. Unciti-Broceta,† J. J. Díaz Mochón & M. Bradley*. Deciphering cellular morphology and biocompatibility using polymer microarrays. Biomedical Materials 2008, 3, 034112 (6pp). † Equal contribution.
Part of the special issue Advanced Processing Routes for Tissue Engineering and Regenerative Medicine.
(9) A. Unciti-Broceta, E. Holder, L. J. Jones, B. Stevenson, A. R. Turner, D. J. Porteous, A. C. Boyd & M. Bradley*. Tripod-Like Cationic Lipids as Novel Gene Carriers. Journal of Medicinal Chemistry 2008, 51, 4076–4084.
Featured in SciBX, 1(25); doi:10.1038/scibx.2008.611 (Nature Publishing Group).
(8) S.-E. How, A. Unciti-Broceta, R. M. Sánchez-Martín & M. Bradley*. Solid-phase synthesis of a lysine-capped bis-dendron with remarkable DNA delivery abilities. Organic & Biomolecular Chemistry 2008, 6, 2266–2269.
(7) A. Unciti-Broceta, J. J. Díaz Mochón, H. Mizomoto & M. Bradley*. Combining Nebulization-Mediated Transfection and Polymer Microarrays for the Rapid Determination of Optimal Transfection Substrates. Journal of Combinatorial Chemistry 2008, 10, 179–184.
Featured in Faculty of 1000 PRIME (Biol. Rep. Ltd)
(6) D. J. Lea-Smith, A. Unciti-Broceta, I. Anderson, J. Parra-Leiton, D. J. Porteous, M. Bradley & C. Boyd. Analysis of a Novel Folate Conjugated PEI Polyplex as a Potential Gene Transfer Agent Targeting Lung Epithelial Cells. Molecular Therapy 2008, 16, Suppl. 1, S189.
(5) F. Khan, R. Zhang, A. Unciti-Broceta, J. J. Díaz-Mochón & M. Bradley*. Flexible Fabrication of Microarrays of Microwells. Advanced Materials 2007, 19, 3524-3528.
(4) A. Unciti-Broceta*, M. J. Pineda-de-las-Infantas, M. A. Gallo & A. Espinosa*. Reduction of Different Electron-Poor N-Heteroarylhydrazines in Strong Basic Conditions. Chemistry, a European Journal 2007, 13, 1754-1762.
(3) A. Unciti-Broceta, M. J. Pineda, J. J. Díaz-Mochón, R. Romagnoli, P. G. Baraldi & A. Espinosa*. Regioselective Synthesis of 9-Alkyl-6-chloropyrido [3,2-e][1,2,4]triazolo[4,3-a]pyrazines. Reactivity of Aliphatic and Aromatic Hydrazides. Journal of Organic Chemistry 2005, 70, 2878-2880.
Featured in ChemInform, 36 (34), 219; doi:10.1002/chin.200534219 (Wiley)
(2) A. Unciti-Broceta. Diseño y síntesis de piridotriazolopirazinas: Evaluación como antagonistas de los receptores adenosínicos. PhD dissertation (Universidad de Granada), 2024.
(1) P. G. Baraldi*, A. Unciti-Broceta, M. J. Pineda de las Infantas, J. J. Díaz-Mochón, A. Espinosa & Romeo Romagnoli. An efficient one-pot synthesis of 6-alkoxy-8,9-dialkylpurines via reaction of 5-amino-4-chloro-6-alkylaminopyrimidines with N,N-dimethylalkaneamides and alkoxide ions. Tetrahedron 2002, 58, 7607-7611.
Featured in ChemInform, 34 (1), 158; doi:10.1002/chin.200301158 (Wiley)